Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:ENLV NASDAQ:IPHA NASDAQ:LTRN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$8.54+6.8%$8.93$1.47▼$14.53$197.73M2.38522,022 shs1.43 million shsENLVEnlivex Therapeutics$0.67-6.8%$0.80$0.66▼$2.10$170.68M1.47412,107 shs178,505 shsIPHAInnate Pharma$1.76+1.1%$1.63$1.17▼$2.63$163.42M0.3137,995 shs420,578 shsLTRNLantern Pharma$3.88-4.7%$2.77$1.11▼$5.74$46.01M2.33256,985 shs132,985 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics+7.82%+4.17%-24.74%+29.45%+308.16%ENLVEnlivex Therapeutics+4.82%-10.82%-5.91%-32.21%-25.16%IPHAInnate Pharma-0.57%-2.79%+27.94%+16.00%-11.94%LTRNLantern Pharma+4.90%+5.93%+97.57%+70.29%+20.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$8.54+6.8%$8.93$1.47▼$14.53$197.73M2.38522,022 shs1.43 million shsENLVEnlivex Therapeutics$0.67-6.8%$0.80$0.66▼$2.10$170.68M1.47412,107 shs178,505 shsIPHAInnate Pharma$1.76+1.1%$1.63$1.17▼$2.63$163.42M0.3137,995 shs420,578 shsLTRNLantern Pharma$3.88-4.7%$2.77$1.11▼$5.74$46.01M2.33256,985 shs132,985 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics+7.82%+4.17%-24.74%+29.45%+308.16%ENLVEnlivex Therapeutics+4.82%-10.82%-5.91%-32.21%-25.16%IPHAInnate Pharma-0.57%-2.79%+27.94%+16.00%-11.94%LTRNLantern Pharma+4.90%+5.93%+97.57%+70.29%+20.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 2.83Moderate Buy$39.00356.67% UpsideENLVEnlivex Therapeutics 2.00Hold$16.502,362.32% UpsideIPHAInnate Pharma 2.50Moderate Buy$5.00184.09% UpsideLTRNLantern Pharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest LTRN, ENLV, ARTV, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026ARTVArtiva Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$41.006/1/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026ARTVArtiva Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/22/2026LTRNLantern Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/12/2026ARTVArtiva Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $41.005/11/2026ARTVArtiva Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $40.005/11/2026ARTVArtiva Biotherapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$23.00 ➝ $40.005/8/2026ARTVArtiva Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $35.005/7/2026LTRNLantern Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026ARTVArtiva Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K844.44N/AN/A$4.48 per share1.91ENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/AIPHAInnate Pharma$10.19M16.22N/AN/A($0.26) per share-6.77LTRNLantern PharmaN/AN/AN/AN/A$0.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$83.86M-$3.54N/AN/AN/AN/A-73.15%-62.74%8/5/2026 (Estimated)ENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%8/24/2026 (Estimated)IPHAInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/AN/ALTRNLantern Pharma-$17.12M-$1.45N/AN/AN/AN/A-198.34%-129.08%8/12/2026 (Estimated)Latest LTRN, ENLV, ARTV, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026LTRNLantern Pharma-$0.36-$0.30+$0.06-$0.30N/AN/A5/8/2026Q1 2026ARTVArtiva Biotherapeutics-$0.88-$0.95-$0.07-$0.95N/AN/A3/30/2026Q4 2025LTRNLantern Pharma-$0.46-$0.36+$0.10-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A8.168.16ENLVEnlivex TherapeuticsN/A193.24193.24IPHAInnate PharmaN/A1.271.27LTRNLantern PharmaN/A1.871.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AENLVEnlivex Therapeutics1.02%IPHAInnate Pharma0.16%LTRNLantern Pharma28.62%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%ENLVEnlivex Therapeutics12.28%IPHAInnate Pharma31.89%LTRNLantern Pharma8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.72 million19.43 millionN/AENLVEnlivex Therapeutics70237.38 million208.23 millionOptionableIPHAInnate Pharma22093.92 million63.97 millionNot OptionableLTRNLantern Pharma2011.31 million10.34 millionOptionableLTRN, ENLV, ARTV, and IPHA HeadlinesRecent News About These CompaniesLantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung CancerJune 2, 2026 | businesswire.comLantern Pharma Highlights Harmonic LP-300 Phase 2 ProgressJune 2, 2026 | tipranks.comLantern Pharma (LTRN) Q1 2025 Earnings TranscriptMay 21, 2026 | finance.yahoo.comLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLCMay 19, 2026 | businesswire.comLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 15, 2026 | businesswire.comInsider Buying: Lantern Pharma (NASDAQ:LTRN) Director Acquires 48,544 Shares of StockMay 15, 2026 | insidertrades.comLantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional InvestorMay 14, 2026 | finance.yahoo.comLantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional InvestorMay 13, 2026 | businesswire.comLantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026May 11, 2026 | businesswire.comLantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery TranscriptApril 30, 2026 | seekingalpha.comLantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery TranscriptApril 30, 2026 | seekingalpha.comLantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization ...April 29, 2026 | finance.yahoo.comLantern Pharma's predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers GloballyApril 29, 2026 | businesswire.comCORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai – A Platform to Conquer Rare CancersApril 26, 2026 | usatoday.comJoin Lantern Pharma on April 30 for the First Public Demonstration of withZeta.ai – A Platform to Conquer Rare CancersApril 24, 2026 | usatoday.comLantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific DebutApril 24, 2026 | businesswire.comEmerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted ...April 21, 2026 | finance.yahoo.comEmerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added ToxicityApril 20, 2026 | businesswire.comLantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut ...April 14, 2026 | finance.yahoo.comLantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22April 14, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTRN, ENLV, ARTV, and IPHA Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$8.54 +0.54 (+6.75%) Closing price 04:00 PM EasternExtended Trading$8.59 +0.05 (+0.57%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Enlivex Therapeutics NASDAQ:ENLV$0.67 -0.05 (-6.80%) Closing price 04:00 PM EasternExtended Trading$0.66 -0.01 (-0.76%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Innate Pharma NASDAQ:IPHA$1.76 +0.02 (+1.15%) Closing price 04:00 PM EasternExtended Trading$1.72 -0.04 (-2.56%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Lantern Pharma NASDAQ:LTRN$3.88 -0.19 (-4.67%) Closing price 04:00 PM EasternExtended Trading$3.92 +0.04 (+1.11%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
